camptothecin has been researched along with Diffuse Large B-Cell Lymphoma in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kadowaki, M; Kohno, K; Kondo, S; Kubota, A; Okamura, S; Takase, K; Takeshita, M; Tanimoto, K; Yamasaki, S | 1 |
| Bartlett, NL; Johnson, JL; Peterson, BA; Ratain, MJ; Wagner-Johnston, N | 1 |
| Barker, JN; Gupta, NK; Noy, A; Young, JW | 1 |
| Kirschbaum, M | 1 |
| Bertrand, R; Liebisch, G; Parent, N; Scherer, M; Schmitz, G | 1 |
| Fukushima, T; Hirose, Y; Karasawa, H; Kawabata, H; Kawanami, T; Masaki, Y; Ogawa, N; Sawaki, T; Shimoyama, K; Sugai, S; Umehara, H; Wano, Y | 1 |
| Bessho, M; Higashihara, M; Kohuri, M; Niitsu, N | 1 |
| Afanasyeva, EA; Bahram, F; Guzhova, IV; Komarova, EY; Larsson, LG; Margulis, BA | 1 |
| Kang, HJ; Kim, BS; Kim, WS; Park, YH; Ryoo, BY; Suh, C; Yuh, YJ | 1 |
| Emoto, Y; Kharbanda, S; Kisaki, H; Kufe, D; Manome, Y | 1 |
| Aggarwal, BB; Mendoza, J; Pantazis, P; Raju, U; Singh, S | 1 |
| Amaya, N; Tsutani, H; Ueda, T; Yamauchi, T; Yoshida, A; Yoshio, N | 1 |
| Asai, J; Fujimoto, T; Miyo, T; Nagashima, G; Suzuki, R | 1 |
3 trial(s) available for camptothecin and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Resistance, Neoplasm; Female; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate | 2009 |
Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Mitoxantrone; Natriuretic Peptide, Brain; NM23 Nucleoside Diphosphate Kinases; Nucleoside-Diphosphate Kinase; Prognosis; Recurrence; Rituximab; Survival Analysis; Survival Rate; Treatment Outcome; Troponin T | 2006 |
Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Irinotecan; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Prednisone; Prospective Studies; Rituximab; Salvage Therapy; Vincristine | 2008 |
10 other study(ies) available for camptothecin and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Dexamethasone; Etoposide; Female; Follow-Up Studies; Glucuronosyltransferase; Humans; Irinotecan; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Recurrence; Treatment Outcome | 2015 |
Fourth complete remission with immunosuppression withdrawal and irinotecan after both autologous and allogeneic transplants for diffuse large B cell lymphoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Cyclosporine; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Irinotecan; Lymphoma, Large B-Cell, Diffuse; Remission Induction; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2009 |
Comeback for the camptothecins?
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Lymphoma, Large B-Cell, Diffuse; Remission Induction; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2009 |
Protein kinase C-δ isoform mediates lysosome labilization in DNA damage-induced apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Ceramides; DNA Damage; Humans; Intracellular Membranes; Isoenzymes; Lymphoma, Large B-Cell, Diffuse; Lysosomes; Mitochondria; Phosphorylation; Protein Kinase C-delta; Proteomics; RNA, Small Interfering; Sphingomyelin Phosphodiesterase; Tumor Cells, Cultured | 2011 |
[Successful salvage therapy of continuous low-dose irinotecan for a patient with relapsed and refractory diffuse large B-cell lymphoma].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Remission Induction; Salvage Therapy; Treatment Outcome | 2005 |
Drug-induced Myc-mediated apoptosis of cancer cells is inhibited by stress protein Hsp70.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Camptothecin; Caspases; Cytochromes c; Enzyme Activation; Enzyme Inhibitors; Estrogens; Etoposide; Gene Expression Regulation, Neoplastic; HSP70 Heat-Shock Proteins; Humans; Lymphoma, Large B-Cell, Diffuse; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-myc; Translocation, Genetic; U937 Cells; Up-Regulation | 2007 |
Activation of protein kinase Cdelta in human myeloid leukemia cells treated with 1-beta-D-arabinofuranosylcytosine.
Topics: Amino Acid Sequence; Apoptosis; Camptothecin; Cytarabine; DNA Damage; Endopeptidases; Enzyme Activation; Genes, jun; Humans; Intracellular Signaling Peptides and Proteins; Isoenzymes; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Membrane Proteins; Mitomycin; Molecular Sequence Data; Myelin Basic Protein; Myristoylated Alanine-Rich C Kinase Substrate; Neoplasm Proteins; Neoplastic Stem Cells; Nucleosomes; Phosphorylation; Protein Kinase C; Protein Kinase C-delta; Protein Processing, Post-Translational; Proteins; Signal Transduction; Substrate Specificity; Tumor Cells, Cultured | 1996 |
Acquisition of cellular resistance to 9-nitro-camptothecin correlates with suppression of transcription factor NF-kappa B activation and potentiation of cytotoxicity by tumor necrosis factor in human histiocytic lymphoma U-937 cells.
Topics: Antineoplastic Agents; Camptothecin; DNA-Binding Proteins; Drug Resistance, Neoplasm; Host Cell Factor C1; Humans; Hydrogen Peroxide; I-kappa B Proteins; Interleukin-1; Lymphoma, Large B-Cell, Diffuse; NF-kappa B; Octamer Transcription Factor-1; Receptors, Tumor Necrosis Factor; Tetradecanoylphorbol Acetate; Transcription Factor AP-1; Transcription Factors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1998 |
Successful salvage treatment with irinotecan (CPT-11) of recurrent malignant lymphoma in an aged patient; and CPT-11 pharmacokinetics.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Recurrence; Salvage Therapy | 1999 |
[Irinotecan (topoisomerase-I inhibitor) for the treatment of recurrent primary intracranial malignant lymphoma].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cerebellar Neoplasms; Cranial Irradiation; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local | 2000 |